Reyk Horland / CEO
Dr. Reyk Horland was appointed CEO of TissUse in October 2020 following 8 years as Head of Business Development. Since 2010 he has implemented a profitable product business with a remarkable annual sales growth rate and has led the market launch of the HUMIMIC® technology in 2014. His business network includes leading pharmaceutical and consumer product companies as well as regulatory authorities and outstanding research institutions worldwide. Prior to TissUse, Dr. Horland studied Biotechnology at the Technische Universität Berlin and specialized in Medical Biotechnology. During his academic career he was involved in various tissue engineering programs, all with a focus on the commercialization of the respective products. He gained experience in marketing and sales in various German companies.
Uwe Marx / CSO
Trained in human biology and medicine, Dr. Uwe Marx is an accomplished entrepreneur and the scientific founder of TissUse. Over the course of his fruitful career in biotechnology, Dr. Marx has pursued ever more lifelike structures that can mimic human biology in vitro. Leading the “Multi-Organ-Chip” development program at the Technische Universität Berlin eventually lead to the foundation of TissUse in 2010, where he served as CEO from 2010 to 2020.
Additionally, Dr. Marx is the scientific co-founder of two other successful Germany-based biotech companies: ProBioGen AG and VITA 34 AG.
In 2022 he was appointed an Honorary Professor of Medical Biotechnology at the Technische Universität Berlin.
Silke Hoffmann / VP Intellectual Property & Innovation
Silke Hoffman, LL.M., came to TissUse from ProBioGen AG, where she served for five years as the intellectual property manager with responsibility for patent administration, freedom-to-operate research and supervision of licensing contracts. Prior to that, she worked for two years at the Max-Delbrück-Center in Berlin as a patent advisor. She studied biochemistry at the Free University of Berlin and then completed a masters degree in commercial property rights at the Humboldt University of Berlin.